BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2019

BIOQUAL, Inc. (OTC Pink: BIOQ) (www.bioqual.com):

 

Nine Months Ended February 28,

     

Three Months Ended February 28,

2019

     

2018

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

2019

     

2018

 
Revenue $ 27,922,919 $ 26,132,351 $ 9,908,572 $ 8,331,395
 
Income Before Income Tax $ 2,357,260 $ 3,824,580 $ 658,274 $ 1,202,918
 
Net Income $ 1,667,760 $ 2,312,980 $ 465,774 $ 799,018
 
Basic Earnings per Share
of Common Stock $ 1.87 $ 2.59 $ .52 $ .89
 
Diluted Earnings per Share
of Common Stock $ 1.87 $ 2.59 $ .52 $ .89
 
Weighted Average
Number of Shares Outstanding
For Basic Earnings Per Share 893,416 893,932 893,416 894,416
 
Weighted Average
Number of Shares Outstanding
For Diluted Earnings Per Share 893,642 893,932 893,642 894,416

For more detail related to the fiscal year 2019 unaudited third quarter results, please visit our web site at www.bioqual.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Companys ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Companys ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Companys contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

Mark G. Lewis, Ph.D., CEO (240-404-7654)